May 6, 2021 -- Altasciences announced it has acquired Calvert Laboratories, a contract research organization (CRO) with operations in Pennsylvania and North Carolina.
The acquisition increases Altasciences' small molecule expertise, as well as adds pharmacology, ophthalmology, and carcinogenicity efficacy study capabilities to its current preclinical offering, the company reported in a statement.
Altasciences is a CRO that supports steps in early-stage drug development. Michael Recny, PhD, is the outgoing CEO of Calvert Laboratories.